Is there an optimal management for localized prostate cancer?
Jaspreet Singh , Edouard J Trabulsi, Leonard G GomellaDepartment of Urology Kimmel Cancer Center Thomas Jefferson University Philadelphia, PA, USAAbstract: Widespread screening with prostate-specific antigen (PSA) has led to a significant increase in the detection of early stage, clinically localize...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2010
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/93a5d75912924df8be875260bb5326b3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Jaspreet Singh , Edouard J Trabulsi, Leonard G GomellaDepartment of Urology Kimmel Cancer Center Thomas Jefferson University Philadelphia, PA, USAAbstract: Widespread screening with prostate-specific antigen (PSA) has led to a significant increase in the detection of early stage, clinically localized prostate cancer (CaP). Various ­treatment options for localized CaP are discussed in this review article including active ­surveillance, radical prostatectomy, radiation therapy, and cyrotherapy. The paucity of high-level evidence adds a considerable amount of controversy when choosing the “optimal” ­intervention, for both the treating physician and the patient. The long time course of CaP intervention outcomes, combined with continuing modifications in treatments, further complicate the ­matter. Lacking randomized trials that compare treatment options, this review article attempts to summarize the different treatment options and associated side-effects, including effects on health-related quality of life, from current published literature.Keywords: prostate cancer, PSA, detection |
|---|